Insulet is trading 4% up at $138.59, with healthcare-sector strength providing the immediate backdrop.
- It rebounded from the 20.12% decline on August 5.
- XLV rose 1.31% during regular trading.
- August 5 earnings showed revenue and adjusted EPS beating estimates, while management lowered full-year growth guidance due to weaker type 2 customer retention and utilization.